SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 13.1% – What’s Next?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) traded up 13.1% during mid-day trading on Friday . The stock traded as high as $12.78 and last traded at $13.2860. Approximately 1,295,199 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 8,510,879 shares. The stock had previously closed at $11.75.

Wall Street Analysts Forecast Growth

SLS has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Monday, July 6th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Price Performance

The stock’s fifty day moving average price is $9.77 and its 200-day moving average price is $6.34. The firm has a market cap of $2.59 billion, a price-to-earnings ratio of -57.35 and a beta of 2.42.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of SELLAS Life Sciences Group by 2.8% in the 3rd quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company’s stock valued at $11,012,000 after purchasing an additional 185,106 shares during the period. Geode Capital Management LLC lifted its position in SELLAS Life Sciences Group by 35.9% in the 4th quarter. Geode Capital Management LLC now owns 3,077,337 shares of the company’s stock worth $11,604,000 after buying an additional 812,953 shares in the last quarter. Marshall Wace LLP lifted its position in SELLAS Life Sciences Group by 23,550.0% in the 2nd quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock worth $5,947,000 after buying an additional 2,704,007 shares in the last quarter. State Street Corp boosted its stake in shares of SELLAS Life Sciences Group by 60.8% during the 4th quarter. State Street Corp now owns 2,188,171 shares of the company’s stock valued at $8,249,000 after buying an additional 827,257 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of SELLAS Life Sciences Group by 341.0% during the 4th quarter. Millennium Management LLC now owns 1,387,849 shares of the company’s stock valued at $5,232,000 after buying an additional 1,073,147 shares during the period. 17.38% of the stock is owned by institutional investors and hedge funds.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.